Pfizer Applies to Swissmedic for Authorisation of Another COVID-19 Vaccine

Reuters staff

September 23, 2022

BERLIN (Reuters) - Pfizer said on Thursday it had submitted an application to Swissmedic for authorisation of a further bivalent COVID-19 vaccine.

The ready-to-use dispersion for injection contained both messenger RNA (mRNA) from the original Pfizer/BioNTech COVID-19 vaccine and mRNA coding for the spike protein of Omicron variants BA.4 and BA.5, Pfizer said.

(Reporting by Kirsti Knolle; Editing by Paul Carrel)